There is a commercial access agreement for durvalumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Durvalumab (Imfinzi, AstraZeneca) with platinum-based chemotherapy as neoadjuvant treatment, and then as monotherapy after surgery, is indicated for 'the treatment of adults with resectable (tumours ≥ ...

University of Sheffield experts said the drug durvalumab could reduce the recurrence of operable bladder cancer by a third Medical experts in Sheffield have hailed as a "game changer" trials of a ...

The study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or returning when treated with immunosurpressant drug durvalumab, and were more ...

Using the immunotherapy drug durvalumab before and after surgery reduced the recurrence of operable bladder cancer by a third, the trial found. Overall survival rates among patients treated with ...

Patients with advanced (muscle-invasive) bladder cancer had significantly less risk of cancer progressing or returning when treated with durvalumab, and were more likely to still be alive two ...